Development of a Novel <i>Shigella</i> Quadrivalent Conjugate Vaccine Using <i>Shigella</i> O-Polysaccharide and IpaB Carrier Protein.

ABSTRACT: Background/Objectives: Shigella is the leading bacterial cause of diarrheal disease worldwide. Although multiple vaccine candidates are under development and in clinical trials, no Shigella vaccine is currently available on the market. Shigella comprises four species: S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. S. flexneri has been recognized as the most prevalent species, particularly in low- and middle-income countries (LMICs), and the top serotypes are S. flexneri 2a, 3a and 6. Conversely, S. sonnei has a single serotype and predominates in high-income countries (HICs). Invasion plasmid antigen B (IpaB) is a critical virulence factor of Shigella type III secretion system (T3SS) t

SUBMITTER: Guo S 

PROVIDER: S-EPMC12945076 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature